alexa Polymorphisms in Genes Encoding Metalloproteinase 9 and Lymphotoxin- Alpha can Influence Warfarin Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Polymorphisms in Genes Encoding Metalloproteinase 9 and Lymphotoxin- Alpha can Influence Warfarin Treatment

Anticoagulant therapy has been increasingly used due to its efficiency and applicability in various pathologies. The most commonly indicated anticoagulant is warfarin, an oral drug that acts inhibiting the synthesis of vitamin K dependent clotting factor. Indications include prevention and treatment of inflammation triggering diseases such as deep vein thrombosis, extensive anterior myocardial infarction, valve prostheses and bioprosthetic (first three months), atrial fibrillation, intracardiac thrombus, among other cardiovascular diseases, which lately are the leading cause of morbidity and mortality worldwide.

Citation: Borges JB, Hirata TDC, Cerda A, Fajardo CM, Cesar RCC,et al. (2015) Polymorphisms in Genes Encoding Metalloproteinase 9 and Lymphotoxin-Alpha can Influence Warfarin Treatment. J Pharmacogenomics Pharmacoproteomics 6:143.

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords